💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Resmetirom

CHEMBL3261331 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
435.2 g/mol
LogP
2.7
Phase
4

Selective agonism at the beta isoform of the thyroid hormone receptor, concentrated in the liver, is the design principle of resmetirom. Activating hepatic THR-beta increases fatty acid oxidation, reduces lipogenesis and improves mitochondrial function, addressing the metabolic dysfunction that drives non-alcoholic steatohepatitis rather than its downstream inflammation alone. Restricting activity to the beta isoform and to hepatic tissue is what avoids the systemic thyrotoxic effects that would follow unselective thyroid receptor stimulation. Approval covers adults with noncirrhotic nonalcoholic steatohepatitis accompanied by moderate to advanced liver fibrosis. The compound is C17H12Cl2N6O4 with a molecular weight near 435.2 g/mol, developed through the final clinical phase.

Resmetirom is a liver-targeted, selective thyroid hormone receptor beta (THR-β) agonist that activates hepatic THR-β to increase hepatic fatty acid oxidation, reduce hepatic lipogenesis, and improve mitochondrial function, directly addressing the metabolic dysfunction driving non-alcoholic steatohepatitis (NASH). It is approved for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis.

Молекулярная масса

435,2000 g/mol

LogP

2,70

TPSA

136,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Endocrinology Hepatology Non-Alcoholic Fatty Liver Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H12Cl2N6O4

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Resmetirom is a liver-targeted, selective thyroid hormone receptor beta (THR-β) agonist that activates hepatic THR-β to increase hepatic fatty acid oxidation, reduce hepatic lipogenesis, and improve mitochondrial function, directly addressing the metabolic dysfunction driving non-alcoholic steatohepatitis (NASH). It is approved for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Resmetirom is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3261331.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 15981237.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.